Article Text

PDF
Intravitreal bevacizumab for choroidal neovascularisation associated with pseudoxanthoma elasticum
  1. R P Finger1,
  2. P Charbel Issa1,
  3. M Ladewig2,
  4. F G Holz1,
  5. H P N Scholl1
  1. 1
    Department of Ophthalmology, University of Bonn, Bonn, Germany
  2. 2
    Department of Ophthalmology, Hospital Saarbrücken, Saarbrücken, Germany
  1. Professor F G Holz, Department of Ophthalmology, University of Bonn, Ernst-Abbe-Str 2, 53127 Bonn, Germany; frank.holz{at}ukb.uni-bonn.de

Abstract

Purpose: To investigate the efficacy of intravitreal bevacizumab injections for treating choroidal neovascularisation (CNV) secondary to pseudoxanthoma elasticum (PXE).

Methods: Patients with active CNV due to PXE received intravitreal bevacizumab (1.5 mg) and were reviewed at monthly intervals. Further treatments were administered depending on disease activity (visual loss of 5 letters or one line, persistent leakage, persistent macular oedema). Baseline and 1–3 monthly follow-up examinations included best corrected visual acuity (BCVA), biomicroscopy, optical coherence tomography (OCT), fluorescein and indocyanine green angiography, fundus autofluorescence and digital fundus photography.

Results: 15 patients (16 eyes) with CNV and PXE were treated. Mean (SD) age was 53 (12.3) years (range 24–72). Mean BCVA at baseline was 20/100 (mean (SD) LogMAR 0.68 (0.51)), improved to 20/63 after the first injection (LogMAR 0.49 (0.45); p = 0.028), and was 20/63 (LogMAR 0.48 (0.48); p = 0.126) at the last follow-up. The mean follow-up time was 8 months. Central retinal thickness decreased significantly from 252 μm at baseline to 214 μm at the last follow-up (p = 0.004) as measured by OCT. Eyes were injected an average of 2.4 times. Categorising patients into two groups (group 1 with only mild changes and group 2 with evident morphological changes in the central macula) revealed that group 1 improved significantly more (LogMAR range 0.41–0.06) than group 2 (LogMAR range 0.80–0.66) (p = 0.014).

Conclusions: The results indicate that intravitreal bevacizumab is effective both functionally and morphologically in treating CNV due to PXE. Best recovery can be achieved in eyes with disease that has not progressed too far and if treatment is initiated at the earliest point possible.

Statistics from Altmetric.com

Footnotes

  • Funding: German Research Foundation (DFG) Heisenberg fellowship SCHO 734/2-1; HO 1926/1-3, 3-1; European Commission (EU) FP6, Integrated Project “EVI-GENORET” (LSHG-CT-2005-512036).

  • Competing interests: None declared.

  • Ethics approval: Ethics approval was obtained.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles